Results from Phase 3 Efficacy Sub-study Presented at the 59 th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists PRISTIQ, which is approved by the U.S. Food and Drug ...
The U.S. Food and Drug Administration wants more information about potential liver and heart-related side effects of Wyeth's WYE experimental treatment for menopausal symptoms before the agency allows ...
Wyeth said yesterday that the FDA will extend its review of Pristiq (desvenlafaxine succinate) to treat menopause symptoms until late July, several months later than expected. The FDA was previously ...
NEW YORK, Dec 12 (Reuters) - Wyeth said on Wednesday that a low-dose 50-milligram form of its experimental Pristiq depression drug was effective in two late-stage trials and far better tolerated than ...
SAN DIEGO, May 8 (Reuters) - Wyeth's experimental drug Pristiq alleviates symptoms of menopause such as hot flashes without a significant impact on sexual function, researchers said on Tuesday, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback